INVESTORS
NEWSROOM
Responsibility
SUBSCRIBE
CONSUMERS
HEALTHCARE PROFESSIONALS
CAREERS
ABOUT ABBOTT
Key products — FreeStyle Libre, MitraClip and Alinity — and strong execution drive impressive growth in 3Q.
We're getting things done. Again.
Our commitment to innovation, our strong execution and our diversified portfolio — which includes key products FreeStyle Libre, MitraClip and Alinity — put us in position to hit our third-quarter 2019 mark.
For the quarter, Abbott met expectations on the top and bottom lines to deliver top-tier sales growth of 7.6% on an organic basis (5.5% reported) and adjusted diluted earnings per share (EPS) of 84 cents (53 cents reported), an increase of 12% versus last year.
Looking ahead, we are on track to achieve the range of sales and EPS growth we set out at the beginning of the year. We’re also narrowing our outlook for 2019 to $3.23 to $3.25 ($2.06 to $2.08 reported) reflecting double-digit growth at the midpoint.
Thanks to our strong product portfolio, a steady cadence of new product approvals, expanded reimbursement coverage and positive clinical data, we are well-positioned to sustain growth for years to come.
Here's a look at some of the quarter highlights:
For full financials, you can read our press release, or take a look at some additional materials below:
Abbott's Chairman and CEO Miles D. White shared his views on third-quarter performance:
Learn more about Abbott's third-quarter 2019 results:
Download a summary of Abbott's earnings highlights here.
For more information on Abbott's earnings results, see the news release.
* Organic sales growth excludes the prior year first-, second- and third-quarter results for a non-core business within U.S. Adult Nutrition, which was discontinued during the third-quarter 2018; and excludes the impact of foreign exchange. For full financial data and reconciliation of non-GAAP measures, please see our press release dated October 16, 2019, available at www.abbottinvestor.com.